Achillion Pharmaceuticals Inc. (ACHN) Trading Down 1.3%
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) dropped 1.3% during mid-day trading on Monday . The stock traded as low as $8.09 and last traded at $8.12, with a volume of 758,900 shares traded. The stock had previously closed at $8.23.
ACHN has been the topic of several research reports. Chardan Capital initiated coverage on Achillion Pharmaceuticals in a report on Thursday, July 14th. They issued a “sell” rating and a $4.00 target price on the stock. Robert W. Baird reaffirmed an “outperform” rating and issued a $10.00 target price on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. Leerink Swann reaffirmed a “hold” rating and issued a $9.00 target price on shares of Achillion Pharmaceuticals in a report on Wednesday, May 25th. JMP Securities raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a report on Thursday, July 7th. Finally, Zacks Investment Research cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $9.63.
The stock’s 50-day moving average is $8.65 and its 200 day moving average is $8.29. The firm has a market capitalization of $1.11 billion and a price-to-earnings ratio of 165.71.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the business earned ($0.25) EPS. Equities research analysts forecast that Achillion Pharmaceuticals Inc. will post ($0.63) EPS for the current fiscal year.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.